期刊文献+

治疗骨髓增殖性肿瘤药物TG101209的合成

Synthetic Technique of TG101209 for Treating Bone Marrow Hyperplastic Tumor
原文传递
导出
摘要 本文研究了治疗骨髓增殖性肿瘤药物TG101209的合成工艺。以2,4-二羟基-5-甲基嘧啶为起始原料,与三氯氧磷、氨水发生氯化、取代反应生成2-氯-4-氨基-5-甲基嘧啶(B),B再与N-叔丁基-3-溴苯磺酰胺(C)发生Buchwald偶联反应得到3-[(2-氯-5-甲基-4-嘧啶基)胺基]-N-(叔丁基)苯磺酰胺(D)。以甲醇为溶剂,D与CH3OH-HCl反应得到3-[(2-氯-5-甲基-4-嘧啶基)胺基]-N-(叔丁基)苯磺酰胺盐酸盐(E),E与1-甲基-4-(4-氨基苯基)哌啶(G)发生亲核取代反应得到N-叔丁基-3-(5-甲基-2-[4-(4-甲基-1-哌嗪)苯胺基]-4-胺基嘧啶)-苯磺酰胺(TG101209)。总收率达到30.9%,HPLC测得纯度达到99.7%。 The synthetic technique of TG101209 for treating bone marrow hyperplastic tumor was studied.2-Chloro-4-amino-5-methyl-pyrimidine(B) was prepared by chlorination and substitution reaction of 2,4-dihydroxy-5-methylpyrimidinnel, phosphorus oxychloride and ammonium hydroxide.B reacted with 3-bromo-N-t-butyl benzenesulfonic amide (C) to give 3-[(2-chloro-5-methyl-4-pyrimidinyl) amino]-N-t-butylbenzenesulfonic amide (D) by Buchwald coupling reaction.D reacted with CH3OH-HCl in the methanol to afford 3- [(2-chloro-5-methyl-4-pyrimidinyl) amino]-N-tert-butylbenzenesuiphonamide hydrochloride (E). (N-tert-butyl-3-(5-methyl-2-[4-(4-methyl-1-piperazinyl)-phenylamino]-pyrimidine-4-ylamino)-benzenesulfonamide)(TG101209) was synthesized by nucleophilic substitution reaction of the intermediate (E) and 1-methyl-4-(4-aminophenyl)piperidine (G). The overall yield was 30.9%. HPLC purity was 99.7%. (N-tert-butyl-3-(5-methyl-2-[4-(4-methyl-1-piperazinyl)-phenylamino]-pyrimidin-4-ylamino)-benzenesulfonamide)(TG101209) was synthesized by nucleophilic substitution reaction of the intermediate (E) and (G).The overall yield was 30.9%.HPLC purity is 99.7%.
出处 《精细化工》 EI CAS CSCD 北大核心 2014年第7期866-869,共4页 Fine Chemicals
基金 国家自然科学基金(21102084) 2011年湖北省自然科学基金项目(2011CDB186)~~
关键词 关键词 N-叔丁基-3·(5-甲基-2-[4-(4-甲基-1-哌嗪)苯胺基]4-胺基嘧啶)-苯磺酰胺 工艺研究 医药与日化原料 N-tert-butyl-3-( 5-methyl-2-[ 4-( 4-methyl-l-piperazinyl )-phenylamino ]-pyrimidine-4- ylamino) -benzenesulfonamide technical study drug and cosmetic materials
  • 相关文献

参考文献9

  • 1Vi Jay R,Teresa K,Jessica H,et al. TG101209,a novel JAK2 inhibitor,has significant in vitro activity in multiple myeloma and displays preferential cytotoxicity for CD451 myeloma ceils [ J]. American Journal of Hematology ,2010,85:675 - 686.
  • 2Wang Y, Fiskus W, Chang D G, et al. Co treatment with panobinostat and JAK2 inhibitor TG101209 atterative neoplastic cells [ J ]. Blood 2009,114:5024 - 5033.
  • 3Well-Knecbt K J, Ott G R, et al. 2,7-Disubstituted-pyrrolotriazine kinase inhibitors with an unusually high degree of reactive metabolite formation [ J ]. Chem Res Toxicol, 2011, 24 : 1994 - 2003.
  • 4Tefferi A. JAK2 inhibitors for myeloproliferative neoplasms: clarifying facts from myths[ J ]. Blood ,2012,119:2721 - 2730.
  • 5Anand S, Stedham F, Gudqin E, et al. Increased basal intracellular signaling patterns do not correlate with JAK2 genotype in human myeloproliferative neoplasm [J]. Blood,2011,118 : 1610 - 1621.
  • 6Pardanan A, Hood J, Lasho T, et al. TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations [J]. Leukemia,2007,21:1658 - 1668.
  • 7CAO J J ,HOOD J. Bi-aryl meta-pyrimidine inhibitors of kinases [ P]. WO :2007/053452 A1,2007 - 05 - 10.
  • 8Ducray R, Boutron P, Didelot M, et al. A versatile route to 3- ( pyrimidin-4-yl ) -imidazo ( 1,2 -a ) pyridines and 3- ( pyrimidin-4- yl) pyrazo ( 1,5-a ) pyridines [ J ]. Tetrahedron letters, 2010,51 (36) :4755.
  • 9Adam M C, Paul A K, Jody M, et al. Synthesis, molecular modeling and biological activity of methyl and thiomethyl substituted pyrimidines as cortieotmpin releasing hormone type 1 antagonists [ J ]. Org Biomol Chem,2003,1 (2) :3353 - 3361.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部